Summary
To investigate whether the variable efficacy in Raynaud's phenomenon of long-term oral ketanserin treatment might be related to variation in the sensitivity of 5-HT2 receptors to ketanserin, serotonin-induced platelet aggregation was measured in ten patients with Raynaud's phenomenon at various times after treatment with ketanserin. Platelet aggregation was completely inhibited 90 min after 40 mg ketanserin, but not 12–14 h after the last dose of 40 mg on the 31st day of continuous twice daily administration. However, 90 min after an additional dose of 40 mg, platelet aggregation was again completely inhibited. The present results indicate that ketanserin 40 mg b.d. does not continuously inhibit platelet 5-HT2 receptors in patients with Raynaud's phenomenon and suggest that more frequent intake might be more effective.
This is a preview of subscription content, log in via an institution to check access.
References
Tomlinson IW (1985) Monitoring cutaneous circulation in Raynaud's phenomenon with observations on ketanserin. Adv Microcirc 12: 37–52
Marasini B, Biondi ML, Bianchi E, Dell'Orto P, Agostoni A (1988) Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon. Eur J Clin Pharmacol 35: 419–421
Allen EV, Brown GE (1932) Raynaud's disease: a critical review of minor requisites for diagnosis. Am J Med Sci 183: 187–200
De Clerck F, Xhonneux B (1985) Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans. J Cardiovasc Pharmacol 7 [Suppl 7]: S23-S25
De Cree J, Leempoels J, Demoen B, Roels V, Verhagen M (1985) Effects of oral ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases. J Cardiovasc Pharmacol 7 [Suppl 7]: S26-S28
Arnout J, Van Russelt M, Deckmyn H, Vermylen J, Fiocchi R, Lijnen P, Amery A (1985) Platelet hypersensitivity to serotonin after prolonged ketanserin intake? J Cardiovasc Pharmacol 7 [Suppl 7]: S20-S22
Arneklo-Nobin B, Elmer O, Akesson A (1988) Effect of long-term ketanserin treatment on 5-HT levels, platelet aggregation and peripheral circulation in patients with Raynaud's phenomenon. A double-blind, placebo-controlled cross-our study. Int Angio 7: 19–25
Trenk D, Mosler A, Kirch W, Meinertz T, Jähnchen E (1983) Pharmacokinetics of the 5-HT2 receptor antagonist ketanserin in man. J Cardiovasc Pharmacol 5: 1034–1039
Biondi ML, Marasini B (1989) Abnormal platelet aggregation in patients with Raynaud's phenomenon. J Clin Pathol 42: 716–718
Winkelman RK, Goldyne ME, Linscheid RL (1976) Hypersensitivity of scleroderma cutaneous vascular smooth muscle to 5-hydroxytrpytamine. Br J Dermatol 195: 51–56
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marasini, B., Biondi, M.L. & Mollica, R. Effect of chronic ketanserin treatment on serotonin-induced platelet aggregation in patients with Raynaud's phenomenon. Eur J Clin Pharmacol 39, 289–290 (1990). https://doi.org/10.1007/BF00315113
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315113